BioSpace News Archive

According to The Insight Partners market research study titled ‘Endoscopy Devices Market - Global Analysis and Forecasts By Product, Application and End User.

HUTCHMED Limited announces the first commercial sale in China of ORPATHYS®, HUTCHMED’s oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase, which occurred on July 12, 2021.

RELIEF THERAPEUTICS Holding AG, NRx Pharmaceuticals, Inc., and Quantum Leap Healthcare Collaborative have announced that they have begun treating patients with inhaled aviptadil in the I-SPY COVID Trial, a phase 2 adaptive platform trial aimed at improving treatment for severely and critically ill COVID-19 patients.

Evrys Bio, a biotech company developing Next Gen Antivirals, was awarded a $34.3 million contract from the Department of Defense to develop a drug, simultaneously effective against multiple high-risk viral agents.

As new CEO of Alligator Bioscience, after just around a month, let me say that my high expectations on the company have been surpassed already.

A recent report by Transparency Market Research states that global smart medical devices market is projected to witness a substantial growth over the tenure of 2016 to 2024.

The vendor landscape of the global reprocessed medical devices market is significantly consolidated with the leading few companies collectively accounting for a lion’s share in the overall market, observes Transparency Market Research in a recent report.

The global genomics personalized health market is anticpated to be highly fragmented due to presence of large number of palyers in the regional and global market.

Transparency Market Research report elucidates the competitive and fragmented global EEG and EMG equiment market. Some of the key players in the global EEG and EMG equipment Masimo Corporation, Nihon kohden Corporation, Electrical Geodesics Inc.,Natus Medical Incorporated, and Cadwell Industries.

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced dosing of the first patient in the Company’s multi-cohort Phase 1/2 study of oral fadraciclib in patients with advanced solid tumors.